Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Esophageal Neoplasms Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Esophageal Neoplasms. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Esophageal Neoplasms clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 / Phase 2 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Cancer Research UK (1), Fudan University (1), Instituto do Cancer do Estado de São Paulo (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is HTL0039732 Capsules (drug, 1 trial), followed by HTL0039732 Capsules and atezolizumab infusion, PD-1 + Omega-3 Fatty Acids (EPA/DHA).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Esophageal Neoplasms trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1 / Phase 2NCT05944237

HTL0039732 in Participants With Advanced Solid Tumours

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other...

Sponsor: Cancer Research UKEnrolling: 1505 locations
RECRUITINGNCT07272382

Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer

This is a randomized, double-blind, placebo-controlled phase II clinical trial designed to evaluate whether adding omega-3 fatty acids improves outcomes in adult patients with...

Sponsor: Fudan UniversityEnrolling: 1421 location
RECRUITINGNCT06070376

Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.

Esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. The main symptom of esophageal cancer...

Sponsor: Instituto do Cancer do Estado de São PauloEnrolling: 341 location
RECRUITINGPhase 1 / Phase 2NCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 21020 locations

Frequently Asked Questions

There are currently 4 clinical trials for Esophageal Neoplasms, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Esophageal Neoplasms, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Esophageal Neoplasms, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.